<DOC>
	<DOCNO>NCT02081014</DOCNO>
	<brief_summary>The purpose study demonstrate mini-doses stable liquid glucagon ( G-Pen Mini ) produce Xeris Pharmaceuticals safe effective treatment mild moderate hypoglycemia , complication diabetes .</brief_summary>
	<brief_title>Safety Efficacy Study Mini-Dose Glucagon ( G-Pen Mini ) Patients With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>1 . Male female subject insulin infusion pump therapy treatment type 1 diabetes 2 . Between age 18 50 year age , inclusive , Screening . 3 . Females childbearing potential negative serum pregnancy test prior screen negative urine pregnancy test prior Treatment visit , use approve form contraception duration participation study ( i.e . last dose ) . 4 . Male subject require use condom another method contraception # 3 start Randomization duration study . 5 . Hemoglobin A1c ( HbA1c ) &lt; 9.0 % . 6 . Evidence personally sign date informed consent document indicate subject inform pertinent aspect study . 7 . Subjects must willing able comply schedule visit , treatment , laboratory test study procedure . 1 . Clinical evidence microvascular complication ( ) mild microalbuminuria history mild nonproliferative retinopathy 2 . Any chronic disease illness interferes glucose metabolism , except T1DM , medication hypothyroidism appropriate thyroid hormone replacement . 3 . Blood pressure ( BP ) read Screening Systemic BP &lt; 90 &gt; 140 mm Hg , Diastolic BP &lt; 50 &gt; 90 mm Hg . 4 . Cardiovascular event within 6 month prior screen unstable angina , acute coronary syndrome , myocardial infarction , therapeutic coronary procedure ( e.g. , stent placement , Percutaneous Transluminal Coronary Angioplasty ( PTCA ) , Coronary Artery Bypass Grafting ( CABG ) ) , stroke transient ischemic attack . 5 . Study participant pregnant Screening . 6 . Breast feeding must discontinue subject wish participate study . 7 . Positive test hepatitis B , hepatitis C , HIV find Screening . 8 . Positive urine drug test illicit drug Screening . 9 . History allergy glucagon , glucagonlike product excipients investigational formulation . 10 . Known presence hereditary problem glycogen storage disease , galactose /or lactose intolerance 11 . Administration glucagon within three ( 3 ) month prior Screening 12 . Subjects follow abnormality clinical laboratory test Screening , confirm single repeat , necessary : Hemoglobin ( Hb ) low limit normal laboratory Total bilirubin upper limit normal laboratory Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) upper limit normal laboratory Creatinine upper limit normal laboratory 13 . History regular alcohol consumption define alcohol intake quantity exceed 7 drink per week female 14 drink per week male , 1 drink = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) hard liquor . 14 . Participation study involve administration investigational drug device within 30 day 5 halflives , whichever longer , screen current study participation current study 15 . Whole blood donation 1 pint ( 500 mL ) within 8 week prior Screening . Donations plasma , pack red blood cell , platelet quantity less 500 mL allow investigator discretion . 16 . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Hypoglycemia</keyword>
	<keyword>Glucagon</keyword>
	<keyword>Diabetes</keyword>
</DOC>